Takeda Pharmaceutical Company

Takeda Pharmaceutical Company is a global, research and development-driven pharmaceutical enterprise headquartered in Tokyo, Japan. Founded in 1781, it is one of the oldest and largest pharmaceutical companies in the world, with a significant presence in over 80 countries and regions. The company focuses on core therapeutic areas including gastroenterology, rare diseases, oncology, neuroscience, and vaccines, operating through a complex structure of subsidiaries and research facilities. Its growth was dramatically accelerated by the landmark acquisition of Shire plc in 2019, which transformed it into a top-tier global biopharmaceutical firm.

History

The company's origins trace back to 1781 when Chobei Takeda I began selling traditional Japanese medicine in Osaka. It was formally incorporated as Chobei Takeda & Co. in 1925. A pivotal early achievement was the production of vitamin B1 in the 1930s, establishing its modern pharmaceutical foundation. Post-World War II, under leaders like Chobei Takeda IV, it expanded rapidly, launching innovative products and establishing Takeda Chemical Industries, Ltd. in 1943. Major international expansion began in the 1970s with ventures into the United States and Europe, including a historic joint venture with Abbott Laboratories to form TAP Pharmaceutical Products. The 21st century saw strategic acquisitions, such as Millennium Pharmaceuticals in 2008 and Nycomed in 2011, before its transformative $62 billion purchase of Shire plc in 2019, one of the largest deals in pharmaceutical history, significantly boosting its pipeline in rare diseases and neuroscience.

Business and operations

Takeda operates through a global business unit structure organized around its key therapeutic areas and a regional commercial model. Its corporate headquarters are in the Nihonbashi district of Tokyo, with significant operational hubs in Cambridge, Massachusetts, Zurich, and Singapore. The company maintains an extensive network of research and development centers, including major sites in Shonan and Fujisawa in Kanagawa Prefecture, the Boston area, and San Diego. Manufacturing facilities are spread across the globe, with key plants in Japan, the United States, Ireland, and Italy. Following the Shire integration, it divested several non-core assets to focus on its strategic priorities, including the sale of its consumer health business to Blackstone Group.

Products and research

Takeda's portfolio includes both innovative medicines and established products. Key blockbuster drugs include Entyvio (vedolizumab) for inflammatory bowel disease, Vyvanse (lisdexamfetamine) for ADHD, and Ninlaro (ixazomib) for multiple myeloma. Its vaccine division, Takeda Vaccines, markets products like the dengue vaccine Qdenga. The company invests heavily in research and development, with a pipeline concentrated in oncology, gastroenterology, and rare diseases. It actively pursues external innovation through partnerships with biotechnology firms and academic institutions like Harvard University and the University of California, San Francisco. Recent R&D efforts have advanced therapies in areas such as gene therapy and mRNA technology.

Corporate affairs

The company is led by President and Chief Executive Officer Christophe Weber and is governed by a board of directors that includes representatives from France, the United States, and Japan. It is a constituent of the Nikkei 225 and is listed on the Tokyo Stock Exchange. Takeda emphasizes corporate social responsibility through its Access to Medicines program and the Takeda Foundation, which supports scientific research. The company's corporate philosophy is rooted in its Takeda-ism values of integrity, fairness, and perseverance. It maintains major sponsorship agreements, including a long-standing partnership with the New York Yankees baseball team.

Controversies and legal issues

Takeda has faced significant legal and regulatory challenges. It was involved in major litigation in the United States concerning its diabetes drug Actos (pioglitazone), with thousands of lawsuits alleging links to bladder cancer, resulting in multi-billion dollar settlements. The company has also settled allegations related to the marketing practices of its former joint venture, TAP Pharmaceutical Products, with the U.S. Department of Justice. More recently, it has faced scrutiny over the safety profile of its dengue vaccine in certain populations and has been involved in patent disputes, such as those concerning Entyvio. These issues have prompted ongoing reviews of its compliance and governance structures.

Category:Pharmaceutical companies of Japan Category:Companies listed on the Tokyo Stock Exchange Category:Companies based in Tokyo Category:Manufacturing companies established in 1781